Cost-effectiveness of mass screening for colorectal cancer: Choice of fecal occult blood test and screening strategy

Diseases of the Colon and Rectum

Volumn 54, Issue 7, 2011, Pages 876-886

  Sobhani, Iradj ^a,b   Alzahouri, Kazem ^b   Ghout, Idir ^b   Charles, Delchier Jean ^a   Durand Zaleski, Isabelle ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Colon cancer; Cost; Immunochemical test; Screening

Indexed keywords

GUAIAC; HEMOGLOBIN; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE CONCEPTS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; MAJOR CLINICAL STUDY; MASS SCREENING; OCCULT BLOOD; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FRANCE; IMMUNOLOGICAL PROCEDURES; INCIDENCE; MALE; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; REPRODUCIBILITY; STATISTICAL MODEL;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; GUAIAC; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC TESTS; INCIDENCE; INDICATORS AND REAGENTS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; OCCULT BLOOD; REPRODUCIBILITY OF RESULTS;

EID: 80051568974     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e31820fd2bc     Document Type: Article

References (31)

1. Bouvier AM, Remontet L, Jougla E, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004;28:877-881. (Pubitemid 39422865)
2. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674-1680. (Pubitemid 38736331)
3. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecaloccult- blood test. Lancet. 1996;348:1467-1471. (Pubitemid 26400241)
4. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477. (Pubitemid 26400242)
5. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-1371. (Pubitemid 23131388)
6. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155-159. (Pubitemid 26017953)
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-2714. (Pubitemid 39665324)
8. Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9:99-103. (Pubitemid 35205230)
9. Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med. 2007; 146:309-311. (Pubitemid 351650618)
10. Zappa M, Castiglione G, Paci E, et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience. Int J Cancer. 2001;92:151-154. (Pubitemid 32187045)
11. Castiglione G, Visioli CB, Ciatto S, et al. Sensitivity of latex agglutination faecal occult blood test in the Florence District population- based colorectal cancer screening programme. Br J Cancer. 2007;96:1750-1754. (Pubitemid 46847191)
12. Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005;115:493-496. (Pubitemid 40663756)
13. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210-214.
14. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338. (Pubitemid 24013155)
15. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397-409. (Pubitemid 28140699)
16. Burt RW. Colorectal cancer screening. Curr Opin Gastroenterol. 2010;26:466-470.
17. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56:677-684. (Pubitemid 46662935)
18. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422-428. (Pubitemid 41096630)
19. Levi Z, Rozen P, Hazazi R, et al.Aquantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244-255. (Pubitemid 351650610)
20. Lejeune C, Arveux P, Dancourt V, Béjean S, Bonithon-Kopp C, Faivre J. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care. 2004; 20:434-439. (Pubitemid 39491490)
21. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-1961.
22. Consensus conference: Prevention Screening and Management of the Colonic Cancers. Paris, France, January 29-30, 1998. Proceedings. Gastroenterol Clin Biol. 1998;22:S1-S295.
23. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer.AmJ Gastroenterol. 1999;94: 1650-1657. (Pubitemid 29260460)
24. Clerc L, Jooste V, Lejeune C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ. 2008;9:361-367.
25. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular- disease risk. Lancet. 2003;361:717-725. (Pubitemid 36293625)
26. Gyrd-Hansen D, Søgaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol. 1997;26:1172-1181. (Pubitemid 28010434)
27. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519-2525.
28. Nakama H, Zhang B, Fattah AS. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer. 2000;36:647-650. (Pubitemid 30156851)
29. Allison JE. Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology. 2005;129:745-748.
30. Berchi C, Bouvier V, Réaud JM, Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2004;13:227-238. (Pubitemid 38292480)
31. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal- cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863-1872. (Pubitemid 44664644)